Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $5.3 million.

  • Cellebrite DI's Cash from Financing Activities fell 472.14% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 5957.4%. This contributed to the annual value of $20.7 million for FY2024, which is 511.83% down from last year.
  • As of Q3 2025, Cellebrite DI's Cash from Financing Activities stood at $5.3 million, which was down 472.14% from $13.8 million recorded in Q2 2025.
  • Cellebrite DI's Cash from Financing Activities' 5-year high stood at $13.8 million during Q2 2025, with a 5-year trough of -$69.5 million in Q3 2021.
  • Moreover, its 5-year median value for Cash from Financing Activities was $4.5 million (2023), whereas its average is $618470.6.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first soared by 43669.81% in 2023, then plummeted by 4157.15% in 2024.
  • Cellebrite DI's Cash from Financing Activities (Quarter) stood at $944000.0 in 2021, then soared by 110.17% to $2.0 million in 2022, then skyrocketed by 128.33% to $4.5 million in 2023, then surged by 48.57% to $6.7 million in 2024, then fell by 21.74% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $13.8 million for Q2 2025, and $3.6 million during Q1 2025.